Announced the completion of its corporate name change to Avaí Bio, Inc. The rebranding, effective today, ...
Announced its participation in the 15th European Pancreas and Islet Transplantation Association (EPITA) ...
Highlights the essential importance of cell encapsulation technology in enabling effective, long-term ...
Issued on behalf of Avant Technologies Inc. VANCOUVER – Baystreet.ca News Commentary – The longevity economy is entering a massive repricing event as researchers confirm that metabolic dysfunction...
Announced a newly published study from the Mayo Clinic reinforces the critical role of the “longevity ...
Avant Technologies Inc. (OTCQB: AVAI) (“Avant” or the “Company”), an emerging biotechnology company focused on developing cellbased therapies for diabetes and age-related disorders, today announced...
Announced that its 50/50 joint venture with Austrianova has entered into an exclusive, worldwide License ...
VANCOUVER – Baystreet.ca News Commentary – The metabolic disorder therapeutics market projects growth to $120.7 billion by 2030 as biotechnology firms pioneer organ-level treatments addressing diabetes,...
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:NTLA),(NASDAQ:ZYME),(NYSE:ANVS) EQNX::TICKER_END
MarketNewsUpdates News Commentary NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The advance anti-aging therapies market is expanding quickly fueled by a larger senior population and increased...